NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Thursday. The company traded as low as $20.95 and last traded at $21.1560, with a volume of 543745 shares trading hands. The stock had previously closed at $22.13.
Analysts Set New Price Targets
Several research analysts recently commented on the company. Jefferies Financial Group reissued a “buy” rating and issued a $45.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. BMO Capital Markets began coverage on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. They issued an “outperform” rating and a $58.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $52.00 price target on shares of NewAmsterdam Pharma in a report on Tuesday, September 8th. Royal Bank Of Canada lowered their price objective on NewAmsterdam Pharma from $50.00 to $42.00 and set an “outperform” rating on the stock in a research note on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, NewAmsterdam Pharma has an average rating of “Moderate Buy” and an average target price of $49.00.
Get Our Latest Stock Analysis on NewAmsterdam Pharma
NewAmsterdam Pharma Price Performance
NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.04). The firm had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $2.83 million. NewAmsterdam Pharma had a negative net margin of 3,644.21% and a negative return on equity of 34.81%. Sell-side analysts expect that NewAmsterdam Pharma Company N.V. will post -1.82 EPS for the current fiscal year.
Insider Transactions at NewAmsterdam Pharma
In related news, Director John W. Smither sold 1,600 shares of NewAmsterdam Pharma stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $25.32, for a total value of $40,512.00. Following the completion of the transaction, the director owned 8,760 shares in the company, valued at approximately $221,803.20. The trade was a 15.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Louise Kooij sold 105,000 shares of the firm’s stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $30.34, for a total transaction of $3,185,700.00. Following the completion of the transaction, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at $738,870.02. This represents a 81.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 281,846 shares of company stock valued at $7,847,619. 12.74% of the stock is owned by insiders.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. Frazier Life Sciences Management L.P. raised its position in NewAmsterdam Pharma by 6.8% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 18,088,902 shares of the company’s stock valued at $613,033,000 after purchasing an additional 1,145,128 shares in the last quarter. Maverick Capital Ltd. increased its stake in shares of NewAmsterdam Pharma by 15.4% during the first quarter. Maverick Capital Ltd. now owns 2,186,402 shares of the company’s stock worth $69,987,000 after buying an additional 292,176 shares during the period. Castle Hook Partners LP acquired a new stake in NewAmsterdam Pharma in the fourth quarter valued at approximately $38,062,000. First Turn Management LLC lifted its stake in NewAmsterdam Pharma by 24.6% in the fourth quarter. First Turn Management LLC now owns 893,473 shares of the company’s stock worth $31,343,000 after acquiring an additional 176,502 shares during the last quarter. Finally, Bank of America Corp DE lifted its stake in NewAmsterdam Pharma by 84.4% in the first quarter. Bank of America Corp DE now owns 847,089 shares of the company’s stock worth $27,115,000 after acquiring an additional 387,698 shares during the last quarter. 89.89% of the stock is owned by institutional investors and hedge funds.
About NewAmsterdam Pharma
NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, with an emphasis on improving the treatment of dyslipidemia and reducing cardiovascular risk. The company’s lead investigational product is obicetrapib, an oral cholesteryl ester transfer protein (CETP) inhibitor designed to lower low-density lipoprotein cholesterol and potentially address other lipid-related abnormalities.
Obicetrapib is being studied as an adjunct to existing lipid-lowering therapies, including in patients who have not achieved adequate cholesterol control and people with heterozygous familial hypercholesterolemia.
Featured Articles
- Five stocks we like better than NewAmsterdam Pharma
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
- This Space ETF Offers SpaceX Exposure—But Investors Are Paying for the Volatilit
- Does Lemonade’s Growth Signal Profits Ahead?
- These 3 ETFs Could Benefit From the Parts of Inflation That Won’t Go Away
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
